2014
DOI: 10.1007/s10815-014-0248-6
|View full text |Cite
|
Sign up to set email alerts
|

Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience

Abstract: Purpose To analyze the cycle outcomes and the incidence of ovarian hyperstimulation syndrome (OHSS), when oocyte maturation was triggered by gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation. Methods One hundred twenty-nine women aged≤45 years, diagnosed with stage≤3 breast cancer, with normal ovarian reserve who desired fertility preservation were included in the retrospective cohort study. Ovarian stimulation w… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

5
48
0
2

Year Published

2015
2015
2022
2022

Publication Types

Select...
5
3

Relationship

2
6

Authors

Journals

citations
Cited by 80 publications
(55 citation statements)
references
References 39 publications
5
48
0
2
Order By: Relevance
“…Reddy et al corroborated that GnRHa trigger arm yielded significantly more mature oocytes and higher fertilization rates than the h CG trigger arm and resulted in lower estrogen levels and OHSS rate in breast cancer patients. 15 These findings have also been inferred by other recent studies.…”
Section: Baseline and Stimulation Cycle Characteristicssupporting
confidence: 84%
“…Reddy et al corroborated that GnRHa trigger arm yielded significantly more mature oocytes and higher fertilization rates than the h CG trigger arm and resulted in lower estrogen levels and OHSS rate in breast cancer patients. 15 These findings have also been inferred by other recent studies.…”
Section: Baseline and Stimulation Cycle Characteristicssupporting
confidence: 84%
“…15 Briefly, letrozole (Novartis Oncology, East Hanover, NJ) 5 mg per day was initiated on cycle day 2 (CD2) followed by gonadotropins (follicle-stimulating hormone; Organon, West Orange, NJ, or follitropin alfa; Serono, Rockville, MD), 150 to 450 IU per day on CD4. 15 Briefly, letrozole (Novartis Oncology, East Hanover, NJ) 5 mg per day was initiated on cycle day 2 (CD2) followed by gonadotropins (follicle-stimulating hormone; Organon, West Orange, NJ, or follitropin alfa; Serono, Rockville, MD), 150 to 450 IU per day on CD4.…”
Section: Methodsmentioning
confidence: 99%
“…Some special considerations should be given to ovarian stimulation for fertility preservation in breast cancer patients. First, the ideal ovarian stimulation regimen for fertility preservation in breast cancer patients should have a low risk of ovarian hyperstimulation syndrome (OHSS), as the majority of these patients will need to start chemotherapy shortly after oocyte retrieval [24,25]. It is also important to reduce estrogen exposure during COH for fertility preservation, as higher hormonal levels may accelerate tumor growth in breast cancer [26].…”
Section: Ovarian Stimulation Protocols In Breast Cancer Patientsmentioning
confidence: 99%
“…Furthermore, the use of antagonist provides the opportunity to use a GnRH agonist to trigger final oocyte maturation, thereby possibly further decreasing the risk of OHSS [24,25]. The use of GnRH agonist trigger can also reduce the time interval from oocyte retrieval to the next menses, because of the suppressive effects that agonists may exert on ovarian response to gonadotropin stimulation [21].…”
Section: Gnrh Antagonist Protocolmentioning
confidence: 99%